Iron deficiency is the most prevalent nutritional disorder globally. Conventional treatment primarily involves oral supplementation with various iron salts, such as ferrous sulfate. While cost-effective and easily administered, these salts are associated with several challenges, including gastrointestinal irritation, prolonged treatment duration, and poor patient compliance due to adverse side effects. To address these limitations, nanotechnology has been employed to develop improved oral iron supplements with varying degrees of success. Utilizing approaches from nanotechnology and materials science, researchers have engineered diverse iron-containing nanomaterials designed to provide bioavailable iron. However, the efficacy of these nanomaterials as oral supplements is highly dependent on their specific physicochemical properties. An effective nano-based replacement for iron salts must exhibit high bioavailability for efficient iron restoration and low toxicity to minimize side effects. This review consolidates in vivo research on various iron nanomaterials evaluated as oral iron supplements. Furthermore, it proposes a framework for the ideal characteristics of an oral iron nanoparticle supplement by consolidating the current understanding of the mechanisms governing nanoparticle absorption and toxicity.
This study aimed to evaluate occupational exposure to respirable crystalline silica (RCS) and assess the lifetime cancer risk (ILCR) and non-cancer hazard quotient (HQ) among ceramic workers. A cross-sectional study was conducted across four occupational groups: polisher/washer, finisher, caster, and material handler. Personal air sampling was performed using NIOSH 7602 methodology to measure time-weighted average (TWA) RCS concentrations. ILCR and HQ were calculated using Monte Carlo simulation with 10,000 iterations, incorporating exposure parameters and health risk models from USEPA guidelines. The mean concentration of respirable crystalline silica (RCS) among workers exceeded both Iran OEL and threshold limit value (TLV) in all four occupational groups, with the highest level observed in Polishers (2.76 mg/m3). Monte Carlo simulation revealed that all groups had Incremental Lifetime Cancer Risk (ILCR) values above the acceptable threshold of 1.00E-06, with polishers showing the highest mean ILCR (5.66E-04). Similarly, Hazard Quotients (HQ) exceeded in all groups, indicating significant non-cancer health risks, particularly in Polishers (mean HQ = 114). These findings indicate a high probability of developing silica-related diseases such as silicosis and lung cancer, emphasizing the need for immediate control measures. The results demonstrate that ceramic workers are exposed to hazardous levels of respirable crystalline silica, posing serious long-term health risks. The use of Monte Carlo simulation provided robust estimates of both carcinogenic and non-carcinogenic risk, confirming the urgent need for regulatory enforcement, engineering controls, respiratory protection, and targeted health education to prevent silica-related diseases in this high-risk population.
This study aimed to elucidate the influence of alcohol, smoking, and substance use on tuberculosis (TB) treatment failure using a meta-analysis approach. A comprehensive search strategy was developed and applied to three major databases: MEDLINE, Web of Science, and Scopus. Additionally, Google Scholar, and Google were used to locate grey literature. Studies were identified through title and abstract screening, followed by a full-text review for eligibility. The Newcastle–Ottawa Scale checklist was employed to assess the quality of included studies. Pooled odds ratios (OR) with 95
CAR-T cell therapy has been transformative in treating certain blood malignancies and is also being adopted for treating other malignancies, including solid tumors. Despite its undeniable successes, CAR-T cell therapy is frequently associated with severe and potentially life-threatening side effects and toxicities, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), graft-versus-host disease (GvHD) in allogeneic settings, secondary CAR-T-derived malignancies, and long-term immunosuppression-induced risk of infections. Recent advances in integrating gene-editing technology and nanomedicine into CAR-T cell therapy have opened new avenues to enhance the safety profile of CAR-T cell therapy and broaden its clinical applications. Gene-editing tools enable targeted modulation of the CAR-T cells' genome, thereby improving their safety profile by preventing related side effects. In parallel, nanomedicine can be used at various stages, including manufacturing and post-treatment, to prevent their occurrence or manage them. This review highlights the current preclinical and clinical landscape, explores the emerging combinatorial strategies, and discusses future directions to achieve a safe and more controllable CAR-T cell therapy.
Multiple sclerosis (MS) is a debilitating autoimmune disorder characterized by inflammatory demyelination and progressive neurodegeneration within the central nervous system (CNS). Despite advances in disease-modifying therapies (DMTs), current treatments primarily mitigate relapses and slow disease progression but fall short in comprehensively addressing cumulative disability or neurodegeneration. Berberine (BBR), a naturally occurring isoquinoline alkaloid, has emerged as a promising therapeutic candidate due to its potent immunomodulatory, anti-inflammatory, and neuroprotective properties. In this narrative review, we synthesize the molecular mechanisms underpinning BBR's effects on MS pathology and evaluate preclinical evidence from MS-relevant animal models. Studies in experimental autoimmune encephalomyelitis (EAE) -the primary MS model-and the cuprizone (CPZ) -induced demyelination model demonstrate that BBR (typically 5-300 mg/kg in preclinical protocols) reduces pro-inflammatory cytokines, modulates immune responses, and promotes remyelination-processes critical for counteracting MS-associated neurodegeneration. BBR modulates key signaling pathways, including JAK/STAT and SPHK1/S1P, which are pivotal in attenuating immune-mediated damage and preserving blood-brain barrier (BBB) integrity. Despite its therapeutic potential, challenges such as poor bioavailability and suboptimal pharmacokinetics have spurred investigations into advanced delivery systems. Nanoformulations, particularly BBR-loaded iron oxide nanoparticles (BBR-IONP), have shown superior efficacy in preclinical models by enhancing CNS delivery and improving remyelination outcomes. By highlighting BBR's multifaceted bioactivities, this review underscores its promise as a complementary or alternative approach to address unmet needs in MS management, while acknowledging the critical need for clinical trials to validate these preclinical findings.